Evidence map›Paper›PMID 34193447›Full record

ArticleBMJ case reports2021

Marked improvement in hyperammonaemic encephalopathy from multimodal treatment of metastatic neuroendocrine tumour.

Alexander Davis, Stephen Clarke, Sally Ayesa, David L Chan

Open access · greenAbstract readCase Reports
In one paragraph

Article in BMJ case reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Alexander DavisMedical Oncology, Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia alexanderpdavis@gmail.com.ORCID http://orcid.org/0000-0001-5390-8133
Stephen ClarkeMedical Oncology, Royal North Shore Hospital, University of Sydney, Royal North Shore Hospital, New South Wales, Australia.
Sally AyesaDepartment of Nuclear Medicine, Royal North Shore Hospital, St Leonards, New South Wales, Australia.
David L ChanMedical Oncology, Royal North Shore Hospital, University of Sydney, Royal North Shore Hospital, New South Wales, Australia.
The University of Sydney · AURoyal North Shore Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gastroenteropancreatic neuroendocrine tumours (GEPNETs) are a heterogenous group of tumours which are rising in incidence. Morbidity and mortality related to these tumours is dependent on the location of metastatic spread. Hyperammonaemia and subsequent encephalopathy has previously been described in GEPNET and is typically associated with a poor prognosis. We describe a case of a 55-year-old woman with hyperammonaemic encephalopathy and a new diagnosis of GEPNET. Given the poor prognosis and the outcomes in this patient group we feel this case highlights the benefit of a multimodality treatment approach including peptide receptor radionucleotide therapy and transarterial chemoembolisation.

Indexed as

Brain DiseasesHyperammonemiaNeuroendocrine TumorsNeurotoxicity SyndromesCombined Modality TherapyFemaleHumansMiddle Agedhepatic canceroncology

Identifiers

PMID34193447
PMCPMC8246280
OpenAlexW3173249359

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.